Stealth BioTherapeutics Corp. ADS
MITO
MITO was delisted on the 15th of November, 2022.
14 hedge funds and large institutions have $1.23M invested in Stealth BioTherapeutics Corp. ADS in 2021 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
17% more funds holding
Funds holding: 12 → 14 (+2)
20% less capital invested
Capital invested by funds: $1.53M → $1.23M (-$306K)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$48.7K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$33.2K |
| 3 |
Two Sigma Advisers
New York
|
+$3.66K |
| 4 |
HF
HRT Financial
New York
|
+$3.21K |
| 5 |
AA
AlphaMark Advisors
Ft. Wright,
Kentucky
|
+$3.13K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$138K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$20.1K |
| 3 |
Renaissance Technologies
New York
|
-$20.1K |
| 4 |
PAM
PVG Asset Management
Golden,
Colorado
|
-$18.7K |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$12.8K |
MITO Hedge Fund Activity: Q3 2021 in Review
14 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Stealth BioTherapeutics Corp. ADS (MITO) for Q3 2021, worth a combined $1.23M — down 20% from $1.53M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new MITO positions and 2 closed out — a net gain of 2 holders — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $48.7K. The largest seller was Goldman Sachs, exiting entirely with an estimated $138K sold.
- 14 institutional investors held Stealth BioTherapeutics Corp. ADS (MITO) as of Q3 2021, up from 12 in Q2 2021.
- Funds reported $1.23M of Stealth BioTherapeutics Corp. ADS stock for Q3 2021, down 20% quarter-over-quarter.
- 4 funds opened new Stealth BioTherapeutics Corp. ADS positions in Q3 2021 and 2 closed out, a net change of +2 holders.
- The largest Stealth BioTherapeutics Corp. ADS buyer in Q3 2021 was Millennium Management, an estimated $48.7K added.
- The largest Stealth BioTherapeutics Corp. ADS seller in Q3 2021 was Goldman Sachs, an estimated $138K sold.
Based on aggregated 13F filings for Q3 2021.